Abstract
INTRODUCTION
Patients with common atrioventricular valve are at increased risk of mortality and adverse outcomes during single ventricle palliation, likely because of the tendency of this valve to become regurgitant [1] [2] [3] [4] . The common atrioventricular valve is prone to failure in biventricular repair, however the rate of failure during the lifetime of a patient with single ventricle physiology is unknown [5, 6] . The presence of regurgitation of common atrioventricular valve has been identified to significantly impact the outcomes of patients with single ventricle, but we still do not know what proportion of patients born with single ventricle and common atrioventricular valve will ultimately see a failure of their valve [2] . We decided to review the data of the Australian and New Zealand Fontan registry to determine the incidence of atrioventricular valve intervention or regurgitation during the lifetime of patients with common atrioventricular valve undergoing single ventricle palliation.
METHODS
The Australian and New Zealand Fontan Registry, created in 2008, includes patients who had their Fontan procedure in either country, as well as patients who had their Fontan procedure overseas who are followed within the region. When the Registry was created, all Fontan procedures were audited retrospectively and this information was entered into the database. Prospective follow-up information has continued to be collected annually for patients who consented to participate in the Registry. The full design, structure and protocol of the Fontan Registry are described elsewhere [7] . A total of 1521 Fontan operations, excluding Bjork procedures, were recorded between January 1975 and April 2016. A total of 53 patients were excluded because they had early Fontan takedown (7) or died in hospital (46). Of the 1468 patients surviving to hospital discharge with a Fontan circulation, 136 patients with common atrioventricular valve were identified. Pre-and peri-operative variables were extracted from the Registry. Follow-up data were extracted from the Registry and were based on clinical summaries detailing echocardiography reports, outpatient appointments and hospital admissions. Data on the presence of atrial isomerism was extracted from clinical files. Patients who had atrioventricular valve procedures or developed moderate or greater atrioventricular valve regurgitation during their lifetime were identified. Twenty-two patients (22/136, 16%) had inadequate follow-up information available (11 patients had follow-up inferior to 2 years, 11 patients had no echocardiographic follow-up available beyond the first 2 years following Fontan). A sensitivity analysis, performed with the inclusion of the 22 patients excluded due to inadequate follow-up information, gave comparable estimates to the main analysis (results not shown). The remaining 114 patients constitute the cohort of this study.
Atrioventricular valve regurgitation
The degree of atrioventricular regurgitation was graded on an ordinal scale of 0 to 3 based on available echocardiography reports and clinical correspondence from initial and pre-Fontan presentation, and during follow-up (0 = none/trivial, 1 = mild, 2 = moderate, 3 = severe).
Definitions
Fontan failure was defined as death, heart transplantation, Fontan takedown, plastic bronchitis, protein-losing enteropathy (PLE) or New York Heart Association functional class III or IV at follow-up. Atrioventricular valve failure was defined as atrioventricular valve repair or replacement or development of moderate or greater atrioventricular valve regurgitation. Atrioventricular valve operation failure was defined as atrioventricular valve reintervention (re-repair or replacement) or the presence of recurrent moderate or greater atrioventricular valve regurgitation at follow-up. Patients were defined to have collaterals if their presence was mentioned in the pre-Fontan catheterization report.
Statistical analyses
Patient baseline characteristics were summarized using mean [standard deviation (SD)] for normally distributed variables, median [interquartile range (IQR)] for non-normally distributed variables and count (%) for categorical variables. Unless stated otherwise the calculation of proportions did not include the missing category. Cox proportional hazard models were used to test the association between potential predictors and time-toevent end-points in univariable analyses. Competing risks regression methods were used for outcomes where death was a competing risk. Multivariable models were not considered due to either small event size or lack of variables reaching statistical significance in univariable models. All statistical analyses were performed in R (Version 3.2.3, http://www.r-project.org/).
RESULTS
Patient characteristics of included and excluded patients are displayed in Table 1 . Seventy-one patients had the following extracardiac anomalies: right atrial isomerism (41), left atrial isomerism (22), intestinal malrotation (1), short stature (1), tracheomalacia (1), Tourette syndrome (1), epilepsy (1), CHARGE syndrome (2), global developmental delay (2), trisomy 21 (1), DiGeorge syndrome (1), Noonan's syndrome (1) and undiagnosed syndrome (1) .
Survival
The median length of follow-up of the 114 patients with a common atrioventricular valve was 10.2 years (IQR 5-15 years). Five deaths were observed. The causes of mortality included seizure (1), death following heart transplant rejection (1), PLE (1), intractable ascites and generalized oedema secondary to unknown cause (1) and unknown (1) . Survival at 10 and 20 years postFontan was 96% (95% CI, 92-100%) and 94% (95% CI, 88-100%), respectively. Three patients ultimately required heart transplantation and one of them subsequently died. Freedom from death or transplantation at 10 and 20 years post-Fontan was 96% (95% CI, 92-100%) and 89% (95% CI, 81-98%) (Fig. 1A ).
Fontan failure
Fontan failure occurred in 21 patients, consisting of 4 deaths, 2 transplants, 8 patients who developed PLE, 3 patients who developed plastic bronchitis and 4 patients who were classified as NYHA class 3 or greater during follow-up. One patient was known to have developed plastic bronchitis but the date was unknown. This patient was excluded from analysis, bringing the sample size to 113 and the number of Fontan failures to 20. The 10 and 20 year freedom from Fontan failure was 84% (95% CI, 76-92%) and 74% (95% CI, 64-87%), respectively (Fig. 1B) . On univariable analysis, extracardiac conduit (ECC) Fontan type was the only predictor of Fontan failure (P = 0.02, Table 2 ).
Analysis of patients with incomplete data
There were 3 deaths among the 22 patients excluded from the principal analysis due to insufficient follow-up compared with 5 deaths among the 114 included patients. In the excluded group, the cause of death was cardiac failure in 2 patients (3 and 14 months post-Fontan) and unknown in 1 patient (3 months postFontan). Excluded patients had a higher proportion of men (73%) compared to the included patients (54% men). Age at Fontan was similar between both groups (median, 5.4 vs 5.5) as was the incidence of dextrocardia (23% vs 20%). The incidence of left [4 (18%) vs 22 (19%)] and right [7 (32%) vs 29 (34%)] heterotaxy was similar between both groups, respectively. Extracardiac anomalies were less prevalent among excluded patients (50%) compared to included patients (62%). Excluded patients had a lower rate of Fontan fenestration (27% vs 39%) and higher proportion of lateral tunnel (9% vs 23%) and extracardiac conduit (77% vs 68%) Fontan procedures.
Atrioventricular valve intervention
There were 28 patients who underwent at least 1 atrioventricular valve procedure. The timing of first atrioventricular valve intervention in relation to other single ventricle palliation procedures is displayed in Table 3 . The median age at first atrioventricular valve procedure was 3.5 years (IQR 2-7 years). There were 24 repairs and 4 replacements. The 10 and 20 years cumulative incidence of atrioventricular valve procedure was 21% (95% CI, 14-29%) and 25% (95% CI, 17-33%), respectively ( Fig. 2A) . Univariable competing risks regression failed to identify any predictors of atrioventricular valve procedure.
Atrioventricular valve regurgitation
In addition to 28 patients undergoing atrioventricular valve procedure, a further 30 patients developed moderate or greater atrioventricular valve regurgitation during their lifetime. Of these patients, 6 were classified as NYHA class III or IV during followup and 10 experienced Fontan failures.
Atrioventricular valve failure
A total of 58 patients reached the composite endpoint of atrioventricular valve failure during their lifetime. The 10-, 20-and 28-year cumulative incidence of valve failure was 34% (95% CI, 25-43%), 48% (95% CI, 37-58%) and 62% (95% CI, 49-74%), respectively (Fig. 2B ). Univariable analysis identified ECC Fontan type (P = 0.01), Fontan fenestration (P = 0.02) and the presence of collaterals (P < 0.01) as predictors of atrioventricular valve failure ( failure for 3 patients and so they were included in the 'no atrioventricular valve failure' group. A further 3 patients experienced Fontan failure before the onset of atrioventricular valve failure and so they were included in the 'no atrioventricular valve failure' group. The rate of Fontan failure was higher among patients who experienced atrioventricular valve failure compared to those who did not (10/52 vs 10/62, HR = 2.6, 95% CI, 1.06-6.41, P = 0.04). For 58 patients with atrioventricular valve failure, freedom from Fontan failure at 5 and 10 years was 93% (95% CI, 86-100%) and 78% (95% CI, 65-93%), respectively. Of the 58 patients with atrioventricular valve failure, 36 were either not offered valve repair or replacement or had an unsuccessful valve intervention. For these 36 patients, Fontan failure occurred in 9 patients (25%), consisting of 1 takedown, 5 patients who developed PLE, 1 patient who developed plastic bronchitis and 2 patients who were classified as NYHA class 3 or greater during follow-up. There was 1 transplant and no deaths observed among this group of patients. Freedom from Fontan failure at 6.8 years was 65% (95% CI, 47-92%) (Fig. 3) .
Durability of valve procedure
Out of the 24 patients undergoing repair as the first atrioventricular valve procedure, 16 patients (67%) experienced failure of the repair. There were 8 re-interventions (6 re-repairs and 2 replacements) and 8 patients developed moderate or greater regurgitation during follow-up. The mean time to reoperation following initial valve repair was 2.9 ± 0.75 years. The 4-year freedom from atrioventricular valve failure post-repair was 50% (95% CI, 34-75%). Durability of atrioventricular valve repair is displayed in Fig. 4 .
Atrioventricular valve replacement
A total of 8 valve replacements were performed on 6 patients. Of 4 patients undergoing replacement as the first atrioventricular valve procedure, 2 patients required re-replacement of the valve (12 and 6 years post-initial replacement, respectively). Of the 6 patients who received a valve replacement, there were 2 deaths and 2 transplants (1 patient had a transplant and subsequently died).
DISCUSSION
Common atrioventricular valve has repeatedly been identified to be a predictor of adverse outcomes along the single ventricle pathway because of the propensity of these valves to leak [1] [2] [3] [4] . Patients with common atrioventricular valve have been identified to be less likely to reach Fontan completion and to be at increased risk of post-Fontan mortality and Fontan failure [1] [2] [3] [4] . In biventricular circulation, common atrioventricular valve is prone to failure [5, 6] . Even in patients with partial atrioventricular septal defects (primum atrial septal defect), common atrioventricular valve has been found to become regurgitant and require reoperation in as many as 25% of patients [5, 6] . A similar incidence has been found in patients with complete atrioventricular septal defect [5, 6, 8] . Until now, the rate of failure of these valves during the lifetime of a patient undergoing single ventricle palliation had not previously been well elucidated. Our results demonstrated that patients with single ventricle physiology and common atrioventricular valve have continuous attrition of their valve function. Two thirds of patients will require valve operation or develop moderate or greater regurgitation during the first three decades of their life. However, this fact hides the real impact of this anatomical feature because our cohort consisted only of patients who had survived the Fontan procedure. The cumulative incidence of valve intervention and significant regurgitation in our group was steadily increasing. It is therefore likely that, with longer follow-up, the incidence of valve failure will continue to rise and one could suspect that all of those valves are ultimately doomed to fail. Interestingly, most of the interventions on these valves occurred before the Fontan stage, but these valves continued to fail well after Fontan completion [4] . These patients received a valve intervention to prepare them for Fontan or concomitantly to it, but not later. Patients with moderate valve regurgitation seemed to have a significant risk of failure of their circulation. Therefore, it is likely that a significant proportion of this population should be offered valve surgery after Fontan completion and that, in the current situation, these patients are not referred for surgery as often as they should be. Interestingly, patients identified to have systemicopulmonary collaterals at the time of the Fontan were at increased risk of seeing their valve fail. It has been suggested to occlude these collaterals at the time of the Fontan and maybe this practice should be further recommended in patients with common atrioventricular valve [9] .
Historically, repair of common atrioventricular valve has produced unreliable results [10] . Some teams have recently reported more encouraging outcomes [11] [12] [13] . We have reported a technique of stabilization of the annulus that we hope will improve outcomes after this challenging surgery [14] . Currently, all the publications presenting favourable outcomes have been limited by the small number of patients reported and short follow-up. The longest follow-up published in such a report was 7 years following 21 patients [15] . In our historical series, repair of common atrioventricular valves produced disappointing results. Half of these repairs failed within 4 years. One should realistically expect that a large proportion of these patients will ultimately require a valve replacement, especially if survival after Fontan continues to extend beyond 3 decades. Three of our patients receiving valve replacement died or required transplantation. This anecdotal experience does not allow us to reach any conclusion about the efficacy of valve replacement in these patients, especially as it is likely that our teams were keeping replacement as a last resort.
It appears that the fate of these valves is to eventually fail. If a technique of stabilization of these valves was proven to be efficient, one could wonder whether a preventative operation could be offered to these patients at the time of Fontan surgery. It could be imagined that stabilization of the central portion of the valve before the development of regurgitation and annular dilatation may be of benefit. We have not yet initiated this strategy but we are contemplating adopting this preventative operation in the near future.
Limitations and strengths
Patients with common atrioventricular valve and atrioventricular valve regurgitation are less likely to reach Fontan completion. The entry point in this study was survival from the Fontan procedure, and accordingly, the selection process may have decreased the incidence of the composite end point of atrioventricular valve failure. This population of 114 patients may seem limited in its ability to predict outcomes. This cohort however, is extracted from one the largest database of its kind and provides the longest follow-up ever on this population. The onset of outcomes were dated at the time the event was first referenced in clinical correspondence available in the Registry. This may impact time to event analyses. ECC Fontan type was found to be a predictor of Fontan failure and the composite endpoint of atrioventricular valve failure. We attributed that finding to the fact that more detailed follow-up information was available in this subgroup of patients, but we cannot eliminate that other parameters may have played a role. As an example, in the recent era, a larger proportion of patients with dysplastic valves may have survived the early stages of palliation and a larger proportion of patients undergoing this more recent technique of Fontan would have worse valve morphology.
CONCLUSION
Patients with single ventricle physiology and common atrioventricular valve have continuous attrition of their valve function. Two thirds of patients will require valve repair or replacement or develop moderate or greater regurgitation in the first three decades of their life. 
